JuddMoulMD

PubMed

• Cognitive and Cerebrospinal Fluid Alzheimer's Disease-related Biomarker Trajectories in Older Surgical Patients and Matched Nonsurgical Controls.
  Melody Reese, Megan K Wong, Vanessa Cheong, Christine I Ha, Mary Cooter Wright, Jeffrey Browndyke, Eugene Moretti, Michael J Devinney, Ashraf S Habib, Judd W Moul, Les...> ;Anesthesiology. 2024 May 1
• Correction: Application of next-generation imaging in biochemically recurrent prostate cancer.
  Pienta, K., Moul, J., Shore, N., Czernin, J., King, M., Freedland, S.> ;Prostate Cancer and Prostatic Diseases. 2024 Jan 17
• 2 citations
  Application of next-generation imaging in biochemically recurrent prostate cancer.
  Judd W Moul, Neal D Shore, Kenneth J Pienta, Johannes Czernin, Martin T King, Stephen J Freedland> ;Prostate Cancer and Prostatic Diseases. 2023 Sep 7
• 2 citations
  Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.
  Neal D Shore, Judd W Moul, Kenneth J Pienta, Johannes Czernin, Martin T King, Stephen J Freedland> ;Prostate Cancer and Prostatic Diseases. 2023 Sep 7
• A multidisciplinary opioid-reduction pathway for robotic prostatectomy: outcomes at year one.
  Michael W Manning, John Whittle, Matthew Fuller, Sara H Cooper, Erin L Manning, Joe Chapman, Judd W Moul, Timothy E Miller> ;Perioperative Medicine. 2023 Aug 1
• 1 citations
  Clinical utility of multiple secondary combined tests in prostate cancer screening.
  John V Dudinec, Sabrina M Wang, Srinath Kotamarti, Kostantinos E Morris, Thomas J Polascik, Judd W Moul> ;The Canadian Journal of Urology. 2023 Jun 1
• AUTHOR REPLY.
  Kostantinos E Morris, Srinath Kotamarti, Thomas J Polascik, Judd W Moul> ;Urology. 2023 May 1
• 2 citations
  Disparities in Prostate Cancer Screening for Transgender Women: An Analysis of the MarketScan Database.
  Hayley Premo, Alexander Gordee, Hui-Jie Lee, Charles D Scales, Judd W Moul, Andrew Peterson> ;Urology. 2023 Jun 1
• 1 citations
  Re-thinking How We Use Prostate Health Index for African American Men.
  Kostantinos E Morris, Srinath Kotamarti, Thomas J Polascik, Judd W Moul> ;Urology. 2023 May 1
• 1 citations
  Molecular Mechanisms of Castrate-Resistant Prostate Cancer.
  Srinath Kotamarti, Andrew J Armstrong, Thomas J Polascik, Judd W Moul> ;The Urologic Clinics of North America. 2022 Nov 1
• 3 citations
  Urinary microbiota and prostatic diseases: the key for the lock? A systematic review.
  Georges Mjaess, Aya Karam, Thierry Roumeguère, Romain Diamand, Fouad Aoun, Kevin McVary, Judd W Moul, Cosimo De Nunzio, Simone Albisinni> ;Prostate Cancer and Prostatic Diseases. 2023 Sep 1
• 1 citations
  Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen.
  Zoe D Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J Armstrong, Rajan T Gupta, Steven Patierno, Nadine J Barrett, Da...> ;The World Journal of Men's Health. 2023 Jul 1
• 1 citations
  How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.
  Judd W Moul, Grannum R Sant> ;The Canadian Journal of Urology. 2022 Aug 1
• 2 citations
  Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer.
  Judd W Moul> ;European Urology Focus. 2022 May 1
• 15 citations
  Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers.
  Miles Berger, Jeffrey N Browndyke, Mary Cooter Wright, Chloe Nobuhara, Melody Reese, Leah Acker, W Michael Bullock, Brian J Colin, Michael J Devinney, Eugene W Moretti...> ;Annals of Clinical and Translational Neurology. 2022 Feb 1
• The long-running disparity in early detection and treatment of prostate cancer in African American men.
  Judd W Moul> ;The Canadian Journal of Urology. 2022 Feb 1
• Editorial Commentary.
  Judd W Moul> ;Urology Practice. 2021 Nov 1
• 11 citations
  Perioperative neurocognitive and functional neuroimaging trajectories in older APOE4 carriers compared with non-carriers: secondary analysis of a prospective cohort st...
  Jeffrey N. Browndyke, Mary Cooter Wright, Rosa Yang, Ayesha Syed, John Park, Ashley Hall, Katherine T. Martucci, Michael J. Devinney, Leslie M. Shaw, Teresa Waligorska...> ;British Journal of Anaesthesia. 2021 Sep 14
• Aggressive prostate cancer masquerading as acute prostatitis.
  Kostantinos Evangelos Morris, Dominic C. Grimberg, Rohith Arcot, Judd W. Moul> ;The Canadian Journal of Urology. 2021 Aug 1
• The type of ADT may matter for testosterone recovery.
  Judd W. Moul> ;The Canadian Journal of Urology. 2021 Aug 1
• Editorial Commentary.
  Judd W Moul> ;Urology Practice. 2021 Jul 1
• Commentary.
  Judd W Moul> ;The Canadian Journal of Urology. 2021 Jun 1
• Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical ...
  E. David Crawford, Jason Hafron, Scott T. Tagawa, Przemyslaw Twardowski, Richard G. Harris, Judd W. Moul, Thomas E. Keane, Raoul S. Concepcion, Celestia S. Higano, Luc...> ;The Journal of Urology. 2021 Feb 1
• 7 citations
  Relationship Between Depression/Anxiety and Cognitive Function Before and 6 Weeks After Major Non-Cardiac Surgery in Older Adults.
  Deborah Oyeyemi, Mary Cooter, Stacey Chung, Heather E. Whitson, Jeffrey N. Browndyke, Michael J. Devinney, Patrick Smith, Grant E. Garrigues, Eugene W. Moretti, Judd W...> ;Journal of Geriatric Psychiatry and Neurology. 2020 Dec 30
• 1 citations
  Are COVID-19 Delays a Basis for Concern? Can We Use This for Future Good?
  Judd W. Moul> ;Oncology. 2020 Sep 15
• Join now to see all

Journal Articles

• Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center.  
  Abern MR, Bassett MR, Tsivian M, Bañez LL, Polascik TJ, Ferrandino MN, Robertson CN, Freedland SJ, Moul JW, Prostate Cancer Prostatic Dis, 1/1/2013
• African-American men with low-grade prostate cancer have higher tumor burdens: Results from the Duke Prostate Center.  
  Tsivian M, Bañez LL, Keto CJ, Abern MR, Qi P, Gerber L, Moul JW, Polascik TJ, Prostate Cancer Prostatic Dis, 1/1/2013
• Preoperative predictors of pathologic stage T2a and pathologic Gleason score < 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: R...  
  Fu Q, Moul JW, Banez L, Sun L, Mouraviev V, Xie D, Polascik TJ, Med Oncol, 1/1/2013
• Sexual bother and function after radical prostatectomy: Predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction.  
  Kimura M, Bañez LL, Polascik TJ, Bernal RM, Gerber L, Robertson CN, Donatucci CF, Moul JW, Andrology, 1/1/2013
• Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.  
  Azrad M, Vollmer RT, Madden J, Dewhirst M, Polascik TJ, Snyder DC, Ruffin MT, Moul JW, Brenner DE, Demark-Wahnefried W, J Med Food, 1/1/2013
• New PSA Recommendations: The Debate over Prostate Cancer Screening Continues  
  LeFevre ML, Moyer VA, D"Amico AV, Moul JW, The ASCO Post, 7/1/2012
• PSA Testing & Prostate Cancer in African-American Men.  
  Moul JW, The Triangle Physician, 3/1/2012
• A critical analysis of the long term impact of radical prostatectomy on cancer control and function outcomes: A systemic review.  
  Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC, European Urology, 1/1/2012
• Prostate cancer: Making the switch from LHRH antagonist to LHRH agonist.  
  Moul JW, Rev Urol, 1/1/2012
• Association between preoperative erectile dysfunction and prostate cancer features - An analysis from the Duke Prostate Center database.  
  Kimura M, Banez LL, Gerber L, Qi J, Tsivian M, Freedland SJ, Satoh T, Polascik TJ, Baba S, Moul JW, J Sex Med, 1/1/2012
• The number of high-risk factors and the risk of prostate cancer - specific mortality after brachytherapy: Implications for treatment selection.  
  Wattson DA, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MH, Salenius SA, D'Amico AV, Int J Radiat Oncol Biol Phys, 1/1/2012
• Role of oxidative stress in a rat model of radiation-induced erectile dysfunction.  
  Kimura M, Rabbani ZN, Zodda AR, Yan H, Jackson IL, Polascik TJ, Donatucci CF, Moul JW, Vujaskovic Z, Koontz BF, J Sex Med, 1/1/2012
• Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonm...  
  Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS, J Urol, 1/1/2012
• Minimally invasive open retropubic prostatectomy: In experienced hands-still the gold standard.  
  Moul JW, Oncology, 1/1/2012
• What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.  
  Catalona WJ, D'Amico AV, Fitzgibbons WF, Omofolasade KL, Leslie SW, Lynch HT, Moul JW, Rendell MS, Walsh PC, Ann Intern Med, 1/1/2012
• Testosterone in prostate cancer: The Bethesda consensus.  
  Djavan B, Eastham J, Gomella L, Tombal B, Taneja S, Dianat SS, Kazzazi A, Shore N, Abrahamsson PA, Cheetham P, Moul J, Lepor H, Crawford ED, BJU Int, 1/1/2012
• When should we pull the trigger for post-radical prostatectomy radiotherapy?  
  Moul JW, European Urology, 1/1/2012
• Masculinity beliefs predict psychosocial functioning in African American prostate cancer survivors.  
  Campbell LC, Keefe FJ, McKee DC, Waters SJ, Moul JW, Am J Mens Health, 1/1/2012
• Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.  
  Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M, Cancer, 1/1/2012
• Preoperative predictors of pathologic t2a in low-risk prostate cancer: Implications for focal therapy.  
  Fu Q, Moul JW, Banez LL, Sun L, Mouraviev V, Xie D, Polascik TJ, Urol Int, 1/1/2012
• Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?  
  Stewart SB, Scales Jr CD, Reed SD, Prostate Cancer Prostatic Dis, 1/1/2012
• NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after r...  
  Moul JW, Lilja H, Semmes OJ, Lance RS, Vessella RL, Fleisher M, Mazzola C, Sarno MJ, Stevens B, Klem RE, McDermed JE, Triebell MT, Adams TH, Urology, 1/1/2012
• Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer.  
  Fu Q, Moul JW, Banez LL, Sun L, Mouraviev V, Xie D, Polascik TJ, Med Oncol, 1/1/2012
• Prostatic Alpha-Linolenic Acid (ALA) is associated with aggressive prostate cancer: A relationship which may depend on genetic variation in ALA metabolism.  
  Azrad M, Zhang K, Vollmer RT, Madden J, Polascik TJ, Snyder DC, Ruffin MT, Moul JW, Brenner D, Hardy RW, Demark-Wahnefried W, PLoS One, 1/1/2012
• Baseline PSA testing at a young age.  
  Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH, European Urology, 1/1/2012
• Join now to see all

Books/Book Chapters

• Conn's Current Therapy 2011. 
  Chapter: Benign Prostatic Hyperplasia. 
  Moul JWEditors: Bope ET, Kellerman RD, Rakel RE.Elsevier, Inc., Burlington, MA.2011
• Comprehensive Textbook of Genitourinary Oncology 
  Banez LL, Freedland SJ, Moul JW. Recurrence Following Radical Prostatectomy: Definitions and ManagementEditors: PT Scardino, MJ Zelefsky, WM Linehan, J Sheinfeld, NJ Vogelzang.Lippincott, Williams & Wilkins, New York, NY.2011
• The 5-Minute Urology Consult, Second Edition. 
  Editors: Gomella LG, Andriole GL, Burnett AL, Casale AJ, Flanigan RC, Keane TE, Moul JW, Thomas R.Lippincott Williams & Wilkins/Wolters Kluwer, Philadelphia, PA.2010
• The American Urological Association Educational Review Manual in Urology. 
  Chapter: Prostate Cancer. 
  Page 353 - 376Moul JW, Hollenbeck BK, Beekman K, Lattanzi J, and Hussain MEditors: AF Morey and DA Shoskes.Castle Connolly Graduate Medical Publishing, Ltd, New York, NY.2009
• Prostate Biopsy: Indications, Techniques, and Complications. 
  Page 287 - 312Fitzsimons NJ, Banez LL, Sun LL, and Moul JWEditors: Jones JS.Humana Press, Totowa, NJ2008
• Prostate Cancer: A Clinical Guide. 
  Moul JWEditors: Gulley JL, Dahut WL, Moul JW, Sandler HM.Lippincott Williams & Wilkins, Philadelphia, PA.2008
• Cancer Management: A Multidisciplinary Approach. 
  Page 393 - 423Moul JW, Armstrong AJ, Hollenbeck BK, Lattanzi J, Bradley D, and Hussain MEditors: R Pazdur, LD Wagman, KA Camphausen, and WJ Hoskins.CMP Healthcare Media, Manhasset, NY.Edition 11th,2008
• Cancer Management: A Multidisciplinary Approach. 
  Chapter: Prostate Cancer. 
  Page 373 - 400Moul JW, Hollenbeck BK, Beekman K, Lattanzi J, and Hussain MEditors: R Pazdur, LR Coia, WJ Hoskins, LD Wagman.CMP Healthcare Media, Manhasset, NY.2007
• The American Urological Association Educational Review Manual in Urology. 
  Page 353 - 376Moul JW, Hollenbeck BK, Beekman K, Lattanzi J, and Hussain MEditors: AF Morey and DA Shoskes.Castle Connolly Graduate Medical Publishing, Ltd, New York, NY.2007
• Rationale for Molecular Markers of Prostate Cancer 
  Chapter: Prostate Cancer: Principles and Practice. 
  Banez LL, Srivastava S, Moul JWEditors: Kirby R, Partin A, Feneley M, Parsons JK.Taylor & Francis2006
• Complete Guide to Prostate Cancer 
  Chapter: Hormonal Therapy (Androgen Deprivation Therapy) 
  Page 215 - 230Amling CL, Moul JWEditors: DG Bostick, ED Crawford, CS Higano and M Roach III.American Cancer Society, Atlanta, GA.2005
• Cancer Management: A Multidisciplinary Approach 
  Chapter: Prostate Cancer. 
  Page 383 - 405Moul JW, Pienta KJ, Hollenbeck BK, Ray MEEditors: R Pazdur, LR Coia, WJ Hoskins, LD Wagman.CMP Healthcare Media, Manhasset, NY.2005
• Management of Prostate Cancer 
  Chapter: Defining an Optimum PSA-Based Screening Strategy for Young Men, Current Clinical Urology 
  Page 37 - 56Moul JWEdition 2nd ,2004
• Prostate Cancer 
  Chapter: Population Screening for Prostate Cancer and Emerging Concepts for Young Men 
  Moul JWEditors: Lucas JN.Nova Science Publishers, Inc., Hauppauge, NY.2004
• Urol 
  Chapter: The Role of Imaging Studies and Molecular Markers for Selecting Candidates for Radical Prostatectomy 
  Page 459 - 472Moul JW, Kane CJ, and Malkowicz SBClinics of North America2001
• The Management of Prostate Cancer. 
  Chapter: Molecular Genetics and Markers of Prostate Cancer Progression. 
  Page 47 - 70Augustus M, Moul JW, Srivastava SEditors: EA Klein.Humana Press, Totowa, NJ2000
• Comprehensive Textbook of Genitourinary Oncology. 
  Chapter: Emerging Prognostic Factors for Outcome prediction in clinically localized prostate cancer: Prostate-Specific Antigen Level, Race, Molecular Markers and Neural Networks. 
  Page 680 - 700D'Amico AV, Moul JW, Kattan MWEditors: N Vogelzang, P Scardino, W Shipley, D Coffey.Lippincott Williams & Wilkins, Philadelphia, PA.2000
• New Perspectives in Prostate Cancer 
  Chapter: Angiogenesis, p53, bcl-2, and Ki-67 in the Progression of Prostate Cancer After Radical Prostatectomy. 
  Page 157 - 168Moul JWEditors: A Belldegrun, RS Kirby, T Oliver.ISIS Medical Media, Oxford, GB.2000
• Radiotherapy of Prostate Cancer 
  Chapter: Is the Evidence for Watchful Waiting Convincing: arguments for Treatment of Clinically Localized Prostate Cancer. 
  Page 49 - 54Moul JW, Burke HBEditors: C Greco, M Zelefsky.Harwood, London2000
• Advanced Therapy of Prostatic Disease 
  Chapter: Assessment of Risk of Prostate Cancer: Algorithms for Diagnosis, Staging, and Prognosis. 
  Page 34 - 43Bauer JJ, Moul JWEditors: M Resnick, IM Thompson.B.C. Decker, Ontario, Canada.2000
• 5 Minute Urology Consult 
  Chapter: Prostate Cancer, General. 
  Page 404 - 407Moul JWEditors: LG Gomella, M Dambro.Lippincott Williams & Wilkins, Philadelphia, PA.2000
• Health Pubs 
  Chapter: Early detection and Screening. 
  Page 219 - 234Denis L, Mettlin C, Carter HB, deKoning HJ, Forcade R, Fornier G, Hugosson J, Kurolthouk V, Moul JW, and Stephenson REditors: G Murphy, S Khoury, A Partin, L Denis.Plymouth, UK2000
• Conn's Current Therapy 
  Chapter: Malignant tumors of the urogenital tract. 
  Moul JW, Costabile RA, Thrasher JBEditors: RE Rakel.Edition 51st,1999
• The Oncobiology of the Prostate 
  Chapter: Molecular Progression of Prostate Cancer. 
  Page 155 - 188Srivastava S, Moul JWEditors: DP Wood, KV Honn.JAI Press, Stanford, CT.1999
• The Molecular genetic phenotype of the malignant prostate. Molecular Pathology of Early Cancers. 
  Page 321 - 340Augustus M, Moul JW, and Srivastava SEditors: Srivastava S, Henson DE, Gazden A.IOS Press1999
• Join now to see all

Abstracts/Posters

• Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer ...
  George DJ, Halabi S, Zurita AJ, Creel P, Mundy K, Turnbull JD, Yenser Wood SE, Armstrong AJ, Varley RJ, Madden J, Moul JW, J Clin Oncol, 1/1/2011
• Switching from leuprolide to degarelix vs continuous degarelix treatment-Effects on long-term prostate-specific antigen control.
  Crawford ED, Moul JW, Shore ND, Olesen TK, Persson B, J Urol, 1/1/2010
• External validation of the SEARCH model for predicting aggressive recurrence after prostatectomy: Results from the Duke Prostate Center database.
  Teeter A, Sun L, Moul J, Freedland S, J Urol, 1/1/2010
• Prostate-Specific Antigen and sesrum alkaline phosphatase levels in prostate cancer patients receiving degarelix or leuprolide.
  Crawford ED, Moul JW, Shore ND, Olesen TK, Persson B, J Urol, 1/1/2010
• Cost-effectiveness of chemoprevention with finasteride for prostate cancer varies across subgroups defined by family history and genetic polymorhisms.
  Reed S, Scales C, Stewart S, Sun J, Moul J, Schulman K, Xu J, J Urol, 1/1/2010
• African-American race is an independent predictor of prostate cancer specific death after PSA recurrence.
  Caso J, Tang P, Tsivian M, Mouraviev V, Polascik T, Moul J, J Urol, 1/1/2010
• Risk stratification for prostate cancer using age-specific PSA quartiles.
  Uhlman M, Sun L, Stackhouse D, Stewart S, Robertson C, Polascik T, Albala D, Moul J, Mouraviev V, J Urol, 1/1/2010
• Initial PSA >= 1.5 ng/ml in men =< 50 years old predicts a subsequent higher risk of prostate cancer.
  Uhlman M, Tang P, Sun L, Robertson C, Polascik T, Albala D, Donatucci C, Moul J, J Urol, 1/1/2010
• Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.
  D'Amico A, Chen M, Sun L, Lee WR, Mouraviev V, Robertson C, Walther P, Polascik T, Albala D, Moul J, J Urol, 1/1/2010
• Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer.
  Crawford ED, Sutton SS, Moul JW, Pettaway CA, Hardin JW, Poston SA, Kruep EJ, J Clin Oncol, 1/1/2010
• Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.
  Shore ND, Moul JW, Crawford ED, Olesen T, Persson B, J Clin Oncol, 1/1/2010
• Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.
  Schroeck FR, Kattan MW, Moul JW, Aronson WJ, Presti Jr JC, Terris MK, Kane CJ, Amling CL, Sun L, Freedland SJ, J Urol, 1/1/2009
• Does pathological gleason score re-review by a modern pathologist improve risk stratification relative to historical gleason score?
  Thomas II JA, Jayachandran J, Banez LL, Sun L, Madden JC, Vollmer RT, Lark AL, Gerber L, Moul JW, Freedland SJ, J Urol, 1/1/2009
• Perineal radical prostatectomy: What are the ten year outcomes?
  Stackhouse DA, Sun L, Dahm P, Kavoussi LR, Paulson D, Donatucci CF, Maloney KE, Albala DM, Polascik TJ, Robertson CN, Moul JW, J Urol, 1/1/2009
• Tumor volume, tumor percentage involvement or prostate volume: Which is predictive of PSA recurrence?
  Uhlman MA, Sun L, Stackhouse DA, Caire AA, Polascik TJ, Mouraviev V, Robertson CN, Albala DM, Moul JW, J Urol, 1/1/2009
• The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: Validation in the ...
  Jayachandran J, Schroeck FR, Sun L, Gerber L, Moreira DM, Moul JW, Freedland SJ, J Urol, 1/1/2009
• Delayed PSA recurrence after radical prostatectomy: How to identify patients at risk and their clinical outcomes?
  Lack BD, Sun L, Caire AA, Ode O, Stackhouse DA, Maloney KE, Donatucci CF, Mouraviev V, Polascik TJ, Robertson CN, Albala DM, Moul JW, J Urol, 1/1/2009
• Cytologic detection of circulating tumor cells in low volume prostate cancer.
  Ali A, Furusato B, Ts'o P O.P., Lum Z-P, Elsamanoudi S, Blake G, Mohamed A, Allen A, Srivastava S, Brassell SA, Moul JW, Sesterhenn IA, McLeod DG, J Urol, 1/1/2009
• Body mass index and prostate-specific antigen as a predictor of adverse pathology and biochemical recurrence following radical prostatectomy.
  Banez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti Jr. JC, Kane CJ, Amling CL, Moul JW, Freedland SJ, J Urol, 1/1/2009
• Prostate-specific antigen recurrence after radical prostatectomy and the risk of death.
  Choueiri TK, Chen M-H, D'Amico AV, Sun L, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW, J Urol, 1/1/2009
• Predicting non-organ confined prostate cancer after the year 2000.
  Caire AA, Sun L, Polascik TJ, Robertson CN, Maloney KE, Donatucci CF, Albala DM, Moul JW, J Urol, 1/1/2009
• Phase I trial of prostatectomy after planned pre-operative radiotherapy for high risk localized prostate cancer: Preliminary results.
  Koontz BF, Quaranta BP, Carroll M, Vujaskovic Z, Lee WR, Robertson CN, Polascik TJ, Anscher MS, Moul JW, J Urol, 1/1/2009
• Who does not need follow up two years after prostatectomy? An analysis of 1739 patients at Duke University Medical Center.
  Lack BD, Sun L, Caire AA, Donatucci CF, Robertson CN, Mouraviev V, Polascik TJ, Albala DM, Maloney KE, Walther PJ, Moul JW, J Urol, 1/1/2009
• Obesity does not impact surgical margin status in robotic prostatectomy.
  Lack BD, Sun L, Zorn KC, Price M, Polascik TJ, Walther PJ, Caire AA, Moul JW, Albala DM, J Urol, 1/1/2009
• Say no to the US Preventative Task Force recommendation to no longer offer prostate cancer screening after age 75?
  Moul JW, Sun L, Lack BD, Robertson CN, Polascik TJ, Donatucci CF, Maloney KE, Price M, Albala DM, Caire AA, J Urol, 1/1/2009
• Join now to see all

Lectures

• 7th Community Oncology Conference 
  Global Academy for Medical Education (Elsevier), Las Vegas, Nevada - 3/30/2012
• Nerve-Sparing Radical Prostatectomy: Open vs. Laparoscopic vs. Robotic: How I do it: Control of Santorini's Plexus, Dissection of Seminal Vesicles. 
  4th World Congress on Controversies in Urology, Paris, France. - 1/27/2011
• The Case for Surgery for High Risk Disease. 
  Genitourinary Cancers Symposium, San Francisco, CA. - 3/5/2010
• Selecting Patients for Active Surveillance: Should Present Criteria Be Enlarged or Reduced? 
  Interactive Genitourinary Cancer Conference, Athens, Greece. - 2/24/2010
• Early Detection, PSA Markers. 
  19th International Prostate Cancer Update, Vail, CO. - 1/29/2009
• Chemoprevention, Who, What, When? 
  Surgical, Pharmacological & Technological Advances in Adult and Pediatric Urology, New York Universi - 12/4/2008
• Prostate Cancer and the Boomers: Who Are They and What Do They Expect from Us? 
  94th Annual Clinical Congress of the American College of Surgeons, Course Moderator, Management of L - 10/12/2008
• Issues/Data in Active Surveillance. 
  NCI-sponsored workshop on "Issues in Clinical Prostate Cancer: Role of Imaging", Rockville, MD. - 6/23/2008
• What's New and in the News with Prostate Cancer in the Baby Boom Generation 2008. 
  David Geffen School of Medicine, UCLA Department of Urology, Los Angeles, CA. - 6/19/2008
• Urology Review for Recertification Candidates, Postgraduate Course. 
  93rd Annual Clinical Congress of the American College of Surgeons, New Orleans, LA. - 10/8/2007
• What's New and in the News with Prostate Cancer. 
  Wake Forest University School of Medicine, Northwest Area Health Education Center. - 11/1/2004
• Prostate Cancer Chemoprevention. 
  Annual Advances in Genitourinary Health: A Scientific Update conference, Chicago, IL. - 10/21/2004
• Prostate Cancer in African American Men: Etiology to Outcomes. 
  Washington Prostate Cancer Disparities Conference, George Washington University Medical Center. - 8/17/2004
• Overview of Advanced Prostate Cancer in the PSA Era. 
  Managing Bone Complications Related to Prostate Cancer, AUA Annual Meeting, San Francisco, CA. - 5/12/2004
• Prostate Cancer Overview. 
  Annual Charles Huggins Symposium AUA Annual Convention, Anaheim, CA. - 6/1/2001
• Take Home Message on Localized Prostate Cancer. 
  AUA Annual Convention, Anaheim, CA. - 6/1/2001
• CPDR Multicenter Prostate Cancer Research Database. 
  Prostate Cancer Congress, San Juan, Puerto Rico. - 6/1/2001
• PSA - only Recurrence of Prostate Cancer. 
  Boston Urological Society, Boston, MA. - 5/1/2001
• Prostate Cancer Update: PSA Recurrence. 
  Richmond Urological Society, Richmond, VA. - 4/1/2001
• Radical Prostatectomy. 
  USUHS Emerging Surgical Technology Conference, Strasbourg, France. - 4/1/2001
• Prostate Cancer Update. 
  Multiple Locations, 1994, 1995, 1996, 1999, 2000, 2001. - 4/1/2001
• Nonsurgical Management of Post Prostatectomy Incontinence. 
  Multiple Locations, 1995, 2001. - 4/1/2001
• Prostate Cancer Research Update. 
  Multiple Locations, 1995, 2001. - 4/1/2001
• Prostate Cancer in African-American Men. 
  Multiple Locations, 1998, 1999, 2001 - 3/1/2001
• Prostate Cancer in the African-American Community. 
  Access Oncology Webcast and monograph, Washington, DC. - 2/1/2001
• Join now to see all

Other

• Individualizing Therapy for the Prostate Cancer Patient: A Growing Set of Options. 
  Moul JW
  Webcast: Virtual Prostate Summit, Duke University, Durham, NC. - 4/17/2012
• What's New in Prostate Cancer Management: A View from the Duke Prostate Center 
  Moul JW
  The Wake County Physician magazine. - 1/1/2009
• Male Stress Incontinence 
  Moul JW
  National Association for Continence, Charleston, SC. - 1/1/2009
• Minimal Disease on Systematic TRUS Biopsy: What Next? 
  Moul JW
  American Urological Association Foundation Webcast. - 8/20/2008
• Panel Findings Reignite Prostate Screening Debate 
  Moul JW
  NBC Nightly News with Brian Williams - 8/5/2008
• Genitourinary Cancers. 
  Moul JW and George DJ
  Your Guide to the Latest Cancer Research and Treatments. CancerCare, New York, NY. - 1/1/2008
• PSA Screening 
  Moul JW
  ABC News, WTVD, Channel 11, Durham, NC (2006); Curtis Media Group (2007) - 12/24/2007
• Meet the Professors: A Case-Based Discussion on the Management of Prostate Cancer in the Localized and Metastatic Settings. 
  Moul JW
  CME Podcast - 10/1/2007
• Advanced, Recurrent Prostate Cancer. 
  Moul JW
  American Urological Association Foundation Webcast. - 9/19/2007
• Prostate Cancer Update: Conversations with Urologic Oncology Investigators - Bridging the Gap Between Research and Patient Care. 
  Moul JW
  CME Podcast - 9/1/2007
• Prostate Cancer 
  Moul JW
  Your Guide to the Latest Cancer Research and Treatments. CancerCare, New York, NY. - 1/1/2007
• PSMA in the Management of Prostate Cancer. 
  Moul JW
  CD-ROM and booklet - 9/1/2006
• Age-Adjusted PSA Velocity Improves Prostate Cancer Screening. 
  Moul JW
  CBS News, WRAL, Channel 5, Raleigh, NC. - 2/28/2006
• Prostate Cancer: A Surgeons' Importance 
  Moul JW
  ABC News, World News Tonight interview with Dr. Timothy Johnson. - 1/24/2006
• Defining Advanced Prostate Cancer. 
  Kane CJ, Moul JW
  Report to the Nation on Prostate Cancer: Focus on Advanced Disease, Prostate Cancer Foundatio - 1/1/2005
• Adjuvant Hormonal Therapy for Locally Advanced Prostate Cancer - the Lancet study. 
  Moul JW
  Satellite Media Tour. - 7/12/2002
• Prostate Health. 
  Moul JW
  Dr. Fishman Show WMAL. - 6/16/2002
• Early Hormonal Therapy for Biochemical Recurrence. 
  Moul JW
  AUA Convention,18 live or taped radio interviews. - 5/30/2002
• Indium-III Capromab Pendetide (ProstaScint) for evaluation of Prostate-Specific antigen-only progression of prostate cancer 
  Moul JW
  1/1/1999
• One-stop shopping for those with prostate cancer. 
  Moul JW
  James Darcy, Pentagram - 9/11/1998
• Sunday Rounds; Prostate Cancer Update. 
  Moul JW
  Radio interview, Syndicated Nationwide program - 6/1/1998
• Blacks more likely to be susceptible: Prostate Cancer Men at Risk. 
  Moul JW
  Eric Rosenberg, Hearst - 1/1/1998
• Prostate Cancer in African-Americans and Screening. 
  Moul JW
  News Channel 21. - 9/9/1996
• African-American Males Have World's Highest Prostate Rate 
  Moul JW
  The Prince George's Post. - 8/15/1996
• Prostate Cancer in Black Men and PSA 
  Moul JW
  The Daily Drum with Herman Washington, WHUR, Washington, DC (1996); WACR, Columbus, MS (1996). - 8/3/1996
• Join now to see all